SV BR 1 GM cancer vaccine - BriaCell Therapeutics

Drug Profile

SV BR 1 GM cancer vaccine - BriaCell Therapeutics

Alternative Names: Allogeneic GM CSF secreting breast cancer vaccine - BriaCell Therapeutics; Bria-IMT™; BriaVax; GM CSF gene-transfected breast cancer vaccine - BriaCell Therapeutics; SV-BR-1-GM; SV-BR-1-GM-vaccine-BriaCell-Therapeutics; SV-BR1-GM-breast-cancer-vaccine-BriaCell-Therapeutics

Latest Information Update: 27 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wiseman Research Initiatives LLC
  • Developer BriaCell Therapeutics Corp; Cancer Insight; Saint Vincent Catholic Medical Centers; Wiseman Research Initiatives LLC
  • Class Cancer vaccines; Gene therapies; Immunotherapies
  • Mechanism of Action CD4-positive T lymphocyte stimulants; Granulocyte colony stimulating factor stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Ovarian cancer

Most Recent Events

  • 21 Jun 2018 SV BR 1 GM cancer vaccine - BriaCell Therapeutics is available for licensing as of 21 Jun 2018. http://briacell.com/
  • 01 Jun 2018 Updated efficacy and adverse events data from a phase I/II trial in Breast cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 18 Apr 2018 Adverse events, efficacy and immunogenicity data from a phase I/IIa trial in Breast cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top